 | Up a level |
Finckh, A; Ciurea, A; Burlhart, L; Möller, B; Walker, UA; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C (2009). Which Subgroup of Rheumatoid Arthritis Patients Benefits Most From Swichting to Rituximab Versus Alternative Anti-TNF Agenst After Previous Failure To Anit-TNF Agent? Annals of the rheumatic diseases, 69(2), pp. 387-393. London: BMJ Publishing Group 10.1136/ard.2008.105064
